







Role of peer support in a national UK hepatitis C elimination program

Davina V Jugnarain

Rachel Halford¹
Stuart Smith¹
Matthew Hickman²
Pantelis Samartsidis³
Graham R Foster

Barts Health Liver Centre, The Blizard Institute, Queen Mary University of London, The Hepatitis C Trust, London UK¹, Population Health Sciences, Bristol Medical School, Bristol University² and MRC Biostatistics Unit, University of Cambridge³



Conflicts of Interest

Professor Foster has received speaker and consultancy fees from Abbvie, Gilead, GSK, MSD

Funding for peers was provided by Abbvie, MSD and Gilead, chiefly as part of the NHSE HCV elimination competitive procurement

Data was analysed independently



Peers and Hepatitis C Elimination Background (i)

- Eliminating HCV infection will require treatment for the majority of infected people
- Many infected people (e.g. drug users, prisoners, the homeless) suffer from low self esteem and fear discrimination
- Overcoming barriers to drug access is critical for HCV elimination



Peers and Hepatitis C Elimination Background (ii)

- Peers are support workers with lived experience of a disease who go on to perform outreach
- Shown to be of benefit for improving access to therapy in mental health, cancer and HIV
- Previous studies have explored the use of peers in HCV but there is no unequivocal evidence of benefit



Peers and Hepatitis C Elimination Aims

To assess the impact of a nationwide program of peer supporters for people with hepatitis C with respect to:-

- Numbers accessing antiviral therapy
- Numbers completing a course of therapy
- Numbers of treatment failures

Outputs were analysed by use, or not, of illicit drugs and by treatment setting



Peers and Hepatitis C Elimination Methods

Therapy in England is provided by 22 networks – 17 had peers Each was provided with a peer based on administrative readiness

	Date of Peers																								
		2017						:	2018										- 2	2019					2020
Peer ODNs	Aug Sept	t Oct	Nov De	c Jan	Feb N	Mar A	pr Ma	y Ju	n Jul	Aug	Sept	Oct	Nov	Dec .	Jan F	eb M	/lar A	pr Ma	y Ju	n Jul	l Aug	Sept	Oct	Nov De	c Jan Fe
Birmingham																									
South Yorkshire																									
Cheshire & Merseyside																									
West Yorkshire																									
Kent Network via Kings																									
Leicester																									
Nottingham																									
Bristol and Severn Hep C ODN																									
Lancashire & South Cumbria																									
North Central London																									
SW Peninsula Hepatitis C ODN																									
Eastern Hepatitis Network																									
Sussex Hepatology Network																									
Thames Valley Hep C ODN																									
Wessex Hep C ODN																									
Excluded																									
South Thames (Kings & St Georges)																									
North East & Cumbria																									
Peers Not Yet Deployed																									
Barts																									
Greater Manchester & Eastern Cheshire																									
Humberside and North Yorkshire																									
Surrey Hepatitis Services																									
West London																									





Peers and Hepatitis C Elimination Methods

Therapy in England is provided by 22 networks – 17 had peers Each was provided with a peer based on administrative readiness

							rs												
		2017					201	8						20	19			2	2020
Peer ODNs	Aug Se	ept Oct	Nov Dec	Jan Fe	b Mar	Apr May	/ Jun J	ul Aug :	Sept	Oct Nov D	ec Ja	n Feb M	ar Apr M	ay Jun	Jul Aug	g Sept (Oct Nov	Dec Ja	n Fel
Birmingham																			
South Yorkshire																			
Cheshire & Merseyside																			
West Yorkshire																			
Kent Network via Kings																			
Leicester																			
Nottingham											~ •					م لم	100		
Bristol and Severn Hep C ODN					15	W	r, l		1	ps	\mathbf{H}	J [O							e
_ancashire & South Cumbria			_																
North Central London									_					_					
SW Peninsula Hepatitis C ODN						ir	141		a		F 1	n				Or			
Eastern Hepatitis Network								U		uc					ノ	CI	3		
Sussex Hepatology Network																			
Thames Valley Hep C ODN																			
Wessex Hep C ODN																			
Excluded																			
South Thames (Kings & St Georges)																			
North East & Cumbria																			
Peers Not Yet Deployed																			
Barts																			
Greater Manchester & Eastern Cheshire																			
Humberside and North Yorkshire																			
Surrey Hepatitis Services																			
West London																			






Peers and Hepatitis C Elimination Methods - What do peers do?

- Peer coordinators were centrally trained by The Hepatitis C Trust
- Volunteers peer support workers conducted 1-to-1 outreach
- Delivered educational talks followed by point-of-care antibody tests



Peers and Hepatitis C Elimination Accounting for temporal effects


- To account for temporal variation we used approaches developed for stepped wedge trials*
- Count outcomes analysed by Bayesian Poisson mixed effects model
 - Generated relative ratios (RR)
- Proportion outcomes analysed by Bayesian Binomial mixed effects model
 - Generated odds ratios (OR)



^{*}Kennedy-Shaffer et al. in 'Novel methods for the analysis of stepped wedge cluster randomized trials' (2020)




Peers and HCV - Consort Diagram





Peers and Hepatitis C Elimination Results – Immediate impact






- 1.12 RR of initiating treatment in peer groups
 - But no change in PWID engagement?
- 2.45 OR of completing treatment
- 1.27 OR of completing an adequate treatment course
- 1.14 OR of attending for SVR12



Peers and Hepatitis C Elimination Results – impact 2 months onwards





- 1.15 RR of initiating treatment
- 2.19 OR of completing treatment
- 1.15 RR of referrals from drug services
- 1.19 OR of patients being treated in drug services



Peers and Hepatitis C Elimination Results – Treatment Failure Rates

Outcomes recorded at SVR12 follow-up

			lmme	diate		2 months							
		Peer	Range or %	Non Peer	Range or %	Peer	Range or %	Non Peer	Range or %				
	Breakthrough	9	0.1	59	0.25	7	0.11	61	0.25				
	Death after initiating treatment	76	1.0	216	0.92	63	1.03	229	0.93				
	Death after SVR12	1	0.0	13	0.06	0	0.00	14	0.06				
	Did not commence treatment	42	0.6	118	0.50	31	0.51	129	0.52				
0	Death before commencing treatment	2	<0.01	14	0.06	2	0.03	14	0.06				
Outcome	Lost to follow up	1178	16.2	3508	15	987	16	3699	15				
	Non-response	44	0.6	196	0.84	35	0.57	205	0.83				
	Relapse	81	1.1	461	2	65	1	477	2				
	SVR 12	3060	42	16412	70	2625	43	16847	69				
	Other	89	1.2	289	1.23	79	1.29	299	1.22				
	Not Completed	2707	37	2154	9	2229	36	2632	11				
	→ Ineligible for SVR12	2205	81	1023	47	1752	79	1476	56				
	→ Data blanks	502	19	1131	53	477	21	1156	44				



Peers and Hepatitis C Elimination Summary

- Largest study of the impact of peers in hepatitis C
- Immediate effect of peers:
 - Beneficial for engagement in treatment both initiation and completion
 - Suggests peers motivate staff and mitigate unconscious bias
- Delayed effect:
 - Benefits emerging in drug services increased referrals and treatment



Peers and Hepatitis C Elimination Limitations

Non-random deployment of peers in networks

 Less data on later treatment outcomes in peer groups e.g. viral clearance at 12 weeks

Registry data not validated but completion is contractually obligated



Peers and Hepatitis C Elimination Conclusion

- Peers have an immediate effect at improving initiation and completion of treatment
- Proportion of injecting drug users commencing treatment did not change, but peers appear to increase referrals and treatment within drug services
- Peers are effective in engaging at-risk groups for treatment of HCV and could accelerate attainment of elimination targets



Acknowledgements & Contributions

- We are thankful to all of the patients who have agreed to participate in our research
- We are indebted to the clinicians and staff of the operational delivery networks who managed the patients and recorded their data.
- We are grateful to the peers and their trainers at the Hepatitis C Trust
- We are grateful to Ceri Townley and the Arden and Gem Commissioning team for assistance and management of the NHSE HCV database.









Thank you for listening! Please direct any questions to <u>d.v.jugnarain@smd17.qmul.ac.uk</u>

